Rx pain medicines hard to find in pharmacies serving minority neighborhoods

May 07, 2004

VANCOUVER -- Finding a pharmacy that carries certain prescription-strength pain medicines might be a big challenge for people living in predominantly non-white neighborhoods, according to a new survey of Michigan pharmacies.

Only half of the pharmacies in non-white areas that were surveyed by a University of Michigan team had even a scant supply of the kinds of drugs used to treat severe chronic pain, such as back and joint aches. That's much lower than the percentage of pharmacies in mostly white areas, where more than 90 percent of pharmacies had the drugs in stock.

Overall, retail chain pharmacies were less likely than independent pharmacies to carry a sufficient stock of the drugs, known as opioid painkillers. And pharmacies in wealthier ZIP codes of any racial makeup tended to have a better supply.

The study, conducted by a pain research team from the U-M Health System, will be presented here on May 7 at the annual meeting of the American Pain Society.

While the researchers didn't delve deeply into the reasons behind the discrepancies they found, previous research has suggested that pharmacies in poorer or higher-crime areas do not stock opioid drugs because of the real or perceived threat of robbery. In addition to their medically useful painkilling properties, many of the drugs have a street value.

The new results echo findings from New York City that were published by a Columbia University team several years ago. But the U-M authors note that their survey covered an entire state, and looked at more drugs: a total of 15, in three categories. If a pharmacy had even one bottle of one drug from each category, it was considered to have an adequate supply.

Half of the pharmacies were in ZIP codes whose population was more than 70 percent non-white, and the other half were randomly sampled from ZIP codes around the state whose populations were more than 70 percent white.

"The key thing we found is that there are differences in availability of medications. If you are a person living in Detroit and you can't walk to the store to get the medications you need to reduce your pain and help you function, this can be a big problem," says Carmen R. Green, M.D., the U-M pain specialist who led the study.

Green launched the study after hearing from a patient who couldn't find a pharmacy in her mostly African-American neighborhood where she could fill a prescription that Green had given her to treat chronic pain. She had to go to a pharmacy in the suburbs to get the pain medication prescription filled.

Green sees patients with all types of pain at the U-M Center for Interventional Pain Medicine, and studies issues affecting them as head of the Michigan Pain Outcomes Study Team. An associate professor of anesthesiology at the U-M Medical School, she has specialized in studying topics relating to race, age and chronic pain, and chairs the American Pain Society's special interest group on Pain and Disparities in Pain Management.

The study she will describe at the APS meeting used data from the 2000 Census, including race, median age and median income by ZIP code. While the researchers did not find an influence on medication availability based on median age, the association with race was strong - and there was an interaction between race and income when both variables were considered together.

Green's team telephoned the 190 pharmacies and asked them about their stocks of medications in three categories: long-acting opioid painkillers, short-acting ones, and combination products that include an opioid and a non-opioid drug.

Pharmacies had to have at least one drug from each category to be considered as having an adequate supply, though Green notes that it would be better to have several choices in order to fill a doctor's exact orders. In all, 71 percent of the pharmacies had an adequate supply of opioids using this definition.

Examples of long-acting opioids include controlled-release oxycodone, often sold as Oxycontin, and controlled-release morphine. Short-acting opioids include meperidine (sold as Demerol), hydromorphone (sold as dilaudid) and immediate-release oxycodone. And combination products included hydrocodone/acetaminophen (sold as Vicodin and Lorcet), and acetaminophen/oxycodone (known as Percocet or Tylox).

"All of these medications, when used appropriately, have tremendous potential to help patients overcome chronic pain that interferes with their ability to work and carry out daily activities," says Green. "But they also carry an addictive and high-inducing potential that makes them attractive on the black market. While we can't say that fear of theft is behind the discrepancy in availability, we know that some of the pharmacists we spoke with admitted this was a factor. However, most pharmacists surveyed said they didn't get much demand for these medicines, which suggests that we need to look at prescription patterns and other factors."

When the researchers looked at individual medications, significant differences between pharmacies in white and non-white areas arose in four of the five long-acting opioids, all five of the short-acting opioids, and two of the five combination products.

When they looked at median income combined with race, there was an interaction between the two factors.

The median income for all the ZIP codes surveyed was $39,322. Among pharmacies in areas below that median, pharmacies in minority ZIP codes were about 16 times less likely to have a sufficient opioid supply than those in white ZIP codes. But among all ZIP codes with a median income at or above that amount, pharmacies in minority ZIP codes were only 4.6 times less likely to have a sufficient opioid supply. However, Green cautions, the sample size is too small to draw many conclusions about this interaction. "We need to examine this issue further," she explains.

"The bottom line is, if a pharmacy doesn't stock a certain medication, a person in pain may end up in a situation where their physician will prescribe pain medication, but the patient can't get the prescription filled," Green concludes. "Given the incredible impact on daily function, quality of life and economic output that chronic pain can have, this is a crucial issue for physicians and health care providers to be sensitive to, when treating patients who live in areas with large minority populations."
In addition to Green, the study was conducted by Carla Talarico, Tamika Washington and S. Khady Ndao-Brumblay. Three members of the team, Andrea Black, Cecelia Calhoun, and Kyungmin Kang, participate in the U-M's Undergraduate Research Opportunity Program.

University of Michigan Health System

Related Chronic Pain Articles from Brightsurf:

Researchers are developing potential treatment for chronic pain
Researchers from the University of Copenhagen have developed a new way to treat chronic pain which has been tested in mice.

Molecular link between chronic pain and depression revealed
Researchers at Hokkaido University have identified the brain mechanism linking chronic pain and depression in rats.

How chikungunya virus may cause chronic joint pain
A new method for permanently marking cells infected with chikungunya virus could reveal how the virus continues to cause joint pain for months to years after the initial infection, according to a study published Aug.

Gastroesophageal reflux associated with chronic pain in temporomandibular joint
Gastroesophageal reflux (GERD) is associated with chronic, painful temporomandibular disorder -- pain in the temporomandibular joint -- and anxiety and poor sleep contribute to this association, according to a study in CMAJ.

One step closer to chronic pain relief
While effective drugs against chronic pain are not just around the corner, researchers from Aarhus University, Denmark, have succeeded in identifying a protein as a future potential target for medicinal drugs.

Gut bacteria associated with chronic pain for first time
In a paper published today in the journal Pain, a Montreal-based research team has shown, for the first time, that there are alterations in the bacteria in the gastrointestinal tracts of people with fibromyalgia.

Nearly 5.4 million cancer survivors suffer chronic pain
A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the United States.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

New target for chronic pain relief confirmed by scientists
A research group at Hiroshima University observed a potential new target for chronic pain treatment.

Menopause symptoms nearly double the risk of chronic pain
In addition to the other health conditions affected by estrogen, it has also been shown to affect pain sensitivity.

Read More: Chronic Pain News and Chronic Pain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.